Beyond statin therapy: a review of the management of residual risk in diabetes mellitus.

Hdl Handle:
http://hdl.handle.net/10147/139337
Title:
Beyond statin therapy: a review of the management of residual risk in diabetes mellitus.
Authors:
Judge, Eoin P; Phelan, D; O'Shea, Donal
Affiliation:
Department of Endocrinology, St Columcille's Hospital, Loughlinstown, Co. Dublin, Ireland.
Citation:
Beyond statin therapy: a review of the management of residual risk in diabetes mellitus. 2010, 103 (9):357-62 J R Soc Med
Journal:
Journal of the Royal Society of Medicine
Issue Date:
Sep-2010
URI:
http://hdl.handle.net/10147/139337
DOI:
10.1258/jrsm.2010.100033
PubMed ID:
20807991
Abstract:
Total cholesterol and low-density lipoprotein (LDL) cholesterol exhibit an independent, strong, continuous correlation with cardiovascular events. The effectiveness of hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in the treatment and prevention of atherosclerosis is well-established. However, despite the lowering of LDL targets and the increased use of statins, patients with type 2 diabetes mellitus (DM) continue to experience a higher proportion of adverse coronary artery disease events. This is as a result of an atherogenic dyslipidaemia, characterized by low levels of high-density lipoprotein and elevated plasma triglyceride concentrations, often with high levels of cholesterol-rich remnant particles. This article will review dyslipidaemia and its role in DM, and will discuss available treatment modalities that address residual cardiovascular risk in this disease.
Item Type:
Article
Language:
en
MeSH:
Atherosclerosis; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin
ISSN:
1758-1095

Full metadata record

DC FieldValue Language
dc.contributor.authorJudge, Eoin Pen
dc.contributor.authorPhelan, Den
dc.contributor.authorO'Shea, Donalen
dc.date.accessioned2011-08-10T14:19:41Z-
dc.date.available2011-08-10T14:19:41Z-
dc.date.issued2010-09-
dc.identifier.citationBeyond statin therapy: a review of the management of residual risk in diabetes mellitus. 2010, 103 (9):357-62 J R Soc Meden
dc.identifier.issn1758-1095-
dc.identifier.pmid20807991-
dc.identifier.doi10.1258/jrsm.2010.100033-
dc.identifier.urihttp://hdl.handle.net/10147/139337-
dc.description.abstractTotal cholesterol and low-density lipoprotein (LDL) cholesterol exhibit an independent, strong, continuous correlation with cardiovascular events. The effectiveness of hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in the treatment and prevention of atherosclerosis is well-established. However, despite the lowering of LDL targets and the increased use of statins, patients with type 2 diabetes mellitus (DM) continue to experience a higher proportion of adverse coronary artery disease events. This is as a result of an atherogenic dyslipidaemia, characterized by low levels of high-density lipoprotein and elevated plasma triglyceride concentrations, often with high levels of cholesterol-rich remnant particles. This article will review dyslipidaemia and its role in DM, and will discuss available treatment modalities that address residual cardiovascular risk in this disease.-
dc.language.isoenen
dc.subject.meshAtherosclerosis-
dc.subject.meshClofibric Acid-
dc.subject.meshDiabetes Complications-
dc.subject.meshDiabetes Mellitus-
dc.subject.meshDrug Therapy, Combination-
dc.subject.meshDyslipidemias-
dc.subject.meshFatty Acids, Omega-3-
dc.subject.meshHumans-
dc.subject.meshHydroxymethylglutaryl-CoA Reductase Inhibitors-
dc.subject.meshNiacin-
dc.titleBeyond statin therapy: a review of the management of residual risk in diabetes mellitus.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, St Columcille's Hospital, Loughlinstown, Co. Dublin, Ireland.en
dc.identifier.journalJournal of the Royal Society of Medicineen
dc.description.provinceLeinster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.